SUMMARY & CONCLUSIONWe view DIAGNOS CARA technology as a leading edge retinal diagnostic platform. It is known that it is leading edge in its field and has been tested extensively in over 15 countries. It is endorsed by top 10 pharma companies and appears to be gaining traction........ The issue is that as a disruptive technology, it takes time for large scale medical systems to make major changes in how it approaches a large scale problem, such as diabetes. We believe that manual scanning, given the issues involved combined with the accuracy and cost of automated scanning, will ultimately become a thing of the past. We believe that DIAGNOS Inc. is very well positioned to take advantage of this. The question is not so much if, but when.............The day of WHEN is coming.........don't be on the outside looking in when it comes!!!.....Management and sales staff are dedicated to making this happen..........They made there sales pitch to the world at the IDF last month!!!!......As the business grows, the longer-term strategy for the Company is to eventually shift more toward standalone deployment of its technology, with others/partners carrying the operating costs, and DIAGNOS acting as a centralized world-wide cloud-based database/processing center (The Company has a secure state-of-the-art facility in Montreal where its software enhances and analyzes retinal images of patients) handling ever larger volumes of transactions, further benefiting from higher related margins and economies of scale.........Over the longer-term, there seems little doubt that as systems improve and more resources are devoted to it, retinal scanning will ultimately provide far reaching benefits for the scanning for a number of conditions, including heart disease. DIAGNOS Inc. is working on this, and if it can become a central player in this field, the financial potential for the company is enormous. Any news regarding developments of DIAGNOS AI technology in the heart disease sector have the potential to catapult the Company share price well beyond our $1/share 12-month target as the size of the heart disease sector is on an order of magnitude dramatically larger than diabetes and would accelerate the Company towards imminent take-over target status!!.....If Google and IBM can get there retinal scanning up and running it would be a momentous opportunity for ADK. The push for change for retinal scanning would be overwhelming and the Governments would be reacting allot quicker!! The worries of competition.... don't fret....there's more than enough of the global pie to go around!